OBJECTIVE: For @entity1 with @entity13571 ( @entity13571 ) refractory to conventional therapy, new treatment strategies aimed at aggressive induction of remission and relapse prevention are being sought. We herein report our single-centre experience in treating four @entity1 with refractory @entity13571 employing non-myeloablative autologous haematopoietic stem cell transplantation (HSCT). METHODS: Four @entity1 with refractory @entity13571 (two with neurovascular @entity2403 , one with neurovascular Sj  gren syndrome, and one with @entity2883 ) were involved in an Institutional Review Board (IRB) and US Food and Drug Administration (FDA) approved phase I clinical trial of high dose chemotherapy and autologous HSCT. Peripheral blood stem cells were mobilised with @entity786 (Cy) and @entity1261 ( @entity1261 ). Conditioning regimen consisted of Cy 200 mg/kg and rabbit anti-thymocyte globulin 5.5 mg/kg intravenously (iv). RESULTS: All four @entity1 tolerated HSCT well without transplant related mortality or any significant @entity137 . At median follow-up of 28 (range 22-36) months all @entity1 were alive. Three @entity1 (one with @entity2403 , one with Sj  gren syndrome, and one with @entity2883 ) entered a sustained remission at 6, 6 and 24 months, respectively, after transplant. They had significant @entity66 or treatment related damage, as measured by the Birmingham @entity1333 Activity Score and @entity1333 Damage Index, respectively. All three @entity1 who achieved remission discontinued immunosuppressive therapy at the time of transplant and have not required treatment since. One @entity1 with @entity2403 and positive for human @entity4107 has not improved after HSCT. CONCLUSION: We suggest non-myeloablative autologous HSCT is an alternative therapy for select @entity1 with @entity13571 refractory to conventional immunosuppressive therapies.

Autologous non-myeloablative haematopoietic stem cell transplantation for refractory XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity13571 :: ('MESH:D056647', 'Disease') :: ['SV', 'systemic vasculitis'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte-colony stimulating factor'] @entity66 :: ('MESH:D004194', 'Disease') :: ['decrease in disease activity and disease'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['Vasculitis'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity2883 :: ('MESH:D014890', 'Disease') :: ['Wegener granulomatosis'] @entity2403 :: ('MESH:D001528', 'Disease') :: ['Behcet disease'] @entity4107 :: ('3126', 'Gene') :: ['leukocyte antigen (HLA)-B51']
@entity13571 :: (MESH:D056647,Disease) :: ['systemic vasculitis']
